Fig. 3: Biophysical characterizations of DOX (CPT-SAHA)/pre-siRNA-coloaded PCL-CP NPs.

a A schematic diagram of the protocol for the preparation of DOX (CPT-SAHA)/pre-siRNA-coloaded PCL-CP NPs. The figure is created with BioRender.com. b Biophysical characterization of DOX (CPT-SAHA)-loaded PCL micelles at various carrier/drug ratios (w/w). n = 3 independent samples. c Sizes and zeta potentials of PCL/DOX (CPT-SAHA)/pre-siRNA complexes at various N/P ratios. n = 3 independent samples. d Sizes and zeta potentials of DOX/pre-siRNA-coloaded PCL-C NPs (coated with CS alone) at various N/P/S ratios. n = 3 independent samples. e Sizes and zeta potentials of DOX/pre-siRNA-coloaded PCL-CP NPs (coated with a mixture of CS and PEG-CS) at various N/P/S(CS)/S(PEG-CS) ratios. n = 3 independent samples. f Cryo-EM characterization of DOX/pre-siRNA-coloaded PCL-CP NPs prepared at a carrier/drug ratio of 10:1 and a N/P/S/S ratio of 10:1:1:0.5. Bar: 20 nm. g Gel retardation assay of DOX/pre-siRNA-coloaded PCL-CP NPs. Carrier/drug ratio = 10:1, N/P/S/S = 10:1:1:0.5. h In vitro release of DOX or CPT-SAHA from PCL-CP NPs in PBS or plasma. n = 3 independent samples. Data are presented as mean ± s.e.m. *p < 0.05. i Chitosanase-mediated degradation of PCL derivatized with lipid with a Schiff-base or amide linker. n = 3 independent samples. Data are presented as mean ± s.e.m. in (c, d, e, h). Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test for comparison in (h). Data are representative of two independent experiments in (f–h) and three independent experiments in (b–e, i). Source data are provided as a Source Data file for (c, d, e, g, h, i).